![Addressing Unmet Patient Needs in Antimicrobial Resistance (AMR): The Vital Role of Industry Partnerships Addressing Unmet Patient Needs in Antimicrobial Resistance (AMR): The Vital Role of Industry Partnerships](https://cdn.magzter.com/1444374281/1675656877/articles/KTazq9uXp1675671199383/ADDRESSING-UNMET-PATIENT-NEEDS-IN-ANTIMICROBIAL-RESISTANCE-AMR-THE-VITAL-ROLE-OF-INDUSTRY-PARTNERSHIPS.jpg)
Mr Maurizio Luongo,
Chief Executive Officer, Menarini Asia-Pacific
Mr Zhao Hong,
President and Chief Executive Officer, SciClone Pharmaceuticals
What are the barriers to access that are impacting patient outcomes in managing antimicrobial resistance? Why do they exist?
Mr Luongo: In line with the World Health Organisation's (WHO)'s objective to tackle the emerging threat of antimicrobial resistance (AMR), Menarini is striving to reduce morbidity and mortality rates by supporting both the responsible use of antibiotics through global antimicrobial stewardship programmes and providing access to novel antibiotics targeting multidrug-resistant infections. However, new treatments alone are insufficient to combat AMR.
The urgent need to accelerate research and development on AMR prevention and care is hampered by the weak pipeline of antibiotic medicines and dearth of anti-infectives that can effectively treat multidrug-resistant infections. Although 60 products¹ are currently in development, the unpredictable, costly and long R&D timelines for antibiotic development impact the availability of new antibiotics. This issue is further exacerbated by the pharmaceutical industry's shift away from antibiotic discovery in favour of medicines targeted towards chronic disease management (e.g., depression and cancer) as they guarantee higher returns on investment.
この記事は BioSpectrum Asia の BioSpectrum Asia Feb 2023 版に掲載されています。
7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。
すでに購読者です ? サインイン
この記事は BioSpectrum Asia の BioSpectrum Asia Feb 2023 版に掲載されています。
7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。
すでに購読者です? サインイン
![Prof. Christian Wolfrum to join NTU as Deputy President and Provost Prof. Christian Wolfrum to join NTU as Deputy President and Provost](https://reseuro.magzter.com/100x125/articles/11639/1979239/aFQSj2cXo1738327652897/PROF-CHRISTIAN-WOLFRUM-TO-JOIN-NTU-AS-DEPUTY-PRESIDENT-AND-PROVOST.jpg)
Prof. Christian Wolfrum to join NTU as Deputy President and Provost
Nanyang Technological University, Singapore (NTU Singapore) has announced that Professor Christian Wolfrum, an eminent biomedical scientist, will be joining the University as the next Deputy President and Provost.
![Japan suggests addition of PVA into drugs for strong antitumour activity Japan suggests addition of PVA into drugs for strong antitumour activity](https://reseuro.magzter.com/100x125/articles/11639/1979239/L7QBK8c9t1738327954522/JAPAN-SUGGESTS-ADDITION-OF-PVA-INTO-DRUGS-FOR-STRONG-ANTITUMOUR-ACTIVITY.jpg)
Japan suggests addition of PVA into drugs for strong antitumour activity
Treatment for more advanced and difficult-to-treat head and neck cancers can be improved with the addition of polyvinyl alcohol (PVA), the same ingredient used in children's glue.
!["Demand for skilled medtech professionals in the Asia Pacific region is growing rapidly" "Demand for skilled medtech professionals in the Asia Pacific region is growing rapidly"](https://reseuro.magzter.com/100x125/articles/11639/1979239/Bh4IoWqD71738326641256/DEMAND-FOR-SKILLED-MEDTECH-PROFESSIONALS-IN-THE-ASIA-PACIFIC-REGION-IS-GROWING-RAPIDLY.jpg)
"Demand for skilled medtech professionals in the Asia Pacific region is growing rapidly"
2024 saw Japanese medtech firm Olympus receiving approval for the company's first cloud-based AI endoscopy devices in the US and Europe, marking a significant milestone in Olympus' efforts to enhance clinical outcomes and operational efficiency in endoscopy, paving the way to launch its upcoming endoscopy solution, the “Intelligent Endoscopy Ecosystem”.
![BeiGene names Giancarlo Benelli as Head of Europe biz BeiGene names Giancarlo Benelli as Head of Europe biz](https://reseuro.magzter.com/100x125/articles/11639/1979239/dtWtyXs321738327727847/BEIGENE-NAMES-GIANCARLO-BENELLI-AS-HEAD-OF-EUROPE-BIZ.jpg)
BeiGene names Giancarlo Benelli as Head of Europe biz
BeiGene, a Hong Kong-headquartered oncology company that intends to change its name to BeOne Medicines Ltd., has announced the appointment of Giancarlo Benelli as Senior Vice President and Head of Europe, effective January 1.
![Korea develops innovative injectable adhesive hydrogel for bone regeneration Korea develops innovative injectable adhesive hydrogel for bone regeneration](https://reseuro.magzter.com/100x125/articles/11639/1979239/3Ds0USfx91738327790862/KOREA-DEVELOPS-INNOVATIVE-INJECTABLE-ADHESIVE-HYDROGEL-FOR-BONE-REGENERATION.jpg)
Korea develops innovative injectable adhesive hydrogel for bone regeneration
A research team from South Korea-based Pohang University of Science and Technology or POSTECH's Department of Chemical Engineering and Graduate School of Convergence Science and Technology, along with the Department of Chemical Engineering, has developed an innovative injectable adhesive hydrogel for bone regeneration.
![When Clinical Trials Suffer From 'Complicated' Interactions When Clinical Trials Suffer From 'Complicated' Interactions](https://reseuro.magzter.com/100x125/articles/11639/1979239/NXkS_2pHM1738327122349/WHEN-CLINICAL-TRIALS-SUFFER-FROM-COMPLICATED-INTERACTIONS.jpg)
When Clinical Trials Suffer From 'Complicated' Interactions
Diversity in culture, language, and data gathering methods will further increase the difficulty of clinical trials as they become more international, particularly with the growing number of sites being employed across China, Japan, South Korea, and India.
![Dr Krishna M Ella receives prestigious INSA India fellowship Dr Krishna M Ella receives prestigious INSA India fellowship](https://reseuro.magzter.com/100x125/articles/11639/1979239/ewbWvQ-3l1738327520276/DR-KRISHNA-M-ELLA-RECEIVES-PRESTIGIOUS-INSA-INDIA-FELLOWSHIP.jpg)
Dr Krishna M Ella receives prestigious INSA India fellowship
Dr Krishna Ella, a distinguished scientist, co-founder and Executive Chairman of Bharat Biotech International, has been recognised with the prestigious India Fellowship of the Indian National Science Academy (INSA) for the year 2025, for his contributions to new knowledge, discoveries, development of new vaccine technologies, noteworthy improvement in existing technologies.
![Bruker launches infrared imaging microscope for pharma and life science research Bruker launches infrared imaging microscope for pharma and life science research](https://reseuro.magzter.com/100x125/articles/11639/1979239/AOv9T23_N1738328062423/BRUKER-LAUNCHES-INFRARED-IMAGING-MICROSCOPE-FOR-PHARMA-AND-LIFE-SCIENCE-RESEARCH.jpg)
Bruker launches infrared imaging microscope for pharma and life science research
US-based Bruker Corporation has announced the launch of the LUMOS II ILIM, a quantum cascade laser (QCL) based infrared (IR) imaging microscope.
![Qiagen increases QIAcuity digital PCR high-order multiplexing capabilities Qiagen increases QIAcuity digital PCR high-order multiplexing capabilities](https://reseuro.magzter.com/100x125/articles/11639/1979239/vrAMheQwA1738328031280/QIAGEN-INCREASES-QIACUITY-DIGITAL-PCR-HIGHORDER-MULTIPLEXING-CAPABILITIES.jpg)
Qiagen increases QIAcuity digital PCR high-order multiplexing capabilities
Qiagen has announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system with a more than two-fold increase in the number of targets that can be simultaneously analysed from a single biological sample.
![Repligen unveils advanced UV-based Variable Pathlength Technology system for biopharma manufacturers Repligen unveils advanced UV-based Variable Pathlength Technology system for biopharma manufacturers](https://reseuro.magzter.com/100x125/articles/11639/1979239/5sZt4mdv41738328195356/REPLIGEN-UNVEILS-ADVANCED-UVBASED-VARIABLE-PATHLENGTH-TECHNOLOGY-SYSTEM-FOR-BIOPHARMA-MANUFACTURERS.jpg)
Repligen unveils advanced UV-based Variable Pathlength Technology system for biopharma manufacturers
US-based Repligen Corporation has announced the commercial launch of its CTech SoloVPE PLUS System, the most advanced UV-based Variable Pathlength Technology system now available to biopharmaceutical manufacturers.